Request Info Medical Affairs Prescribing Information Important Safety Information Visit Patient Site

For adults with CIDP stabilized on IVIg

PROVEN CIDP CONTROL

Greater Freedom for Everyday Living

Hizentra first FDA-Approved subcutaneous Ig for CIDP
Hizentra CIDP branding image
Hizentra CIDP branding image
Proven icon

Proven
Efficacy & Safety

View results from the largest Ig study in CIDP
Flexible icon

Flexible
To Meet Patient Needs

Explore the benefits of Hizentra
Self-administration icon

Convenient
Dosing & Administration

Utilize the dosing calculator

Hizentra is indicated for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.

  • Limitation of Use: Maintenance therapy in CIDP has been systematically studied for 6 months and for a further 12 months in a follow-up study. Continued maintenance beyond these periods should be individualized based on patient response and need for continued therapy.

SCIg is supported by a professional guideline

The EAN/PNS* guideline on diagnosis and treatment of CIDP “strongly recommends” SCIg for CIDP maintenance1

See SCIg highlights
*EAN/PNS=European Academy of Neurology/Peripheral Nerve Society.

Insights from a CSL-sponsored Harris Poll survey†

Most CIDP patients surveyed preferred SCIg over IVIg2

Of patients surveyed who have used both IVIg and SCIg, 3 out of 4 preferred SCIg

†In an online survey, 22 of 29 adults with CIDP who have used both IVIg and SCIg preferred SCIg.
preferred method of administration

Explore how Hizentra enhances patient experience and impacts lives

Hizentra offers greater flexibility to personalize treatment to fit patients’ lives, addressing clinical challenges and lifestyle burdens associated with IVIg. See how Hizentra provides consistent Ig levels and more.

See patient types Hizentra can help

Meet Arthur, a patient with CIDP discussing his experience of self-infusing Hizentra

Not just simple.
Hizentra PFS simple.

Hizentra Prefilled Syringes (PFS) give your patients
proven protection with a first and only for Ig

Hizentra Prefilled Syringes (PFS) give your patients proven protection with a first and only for Ig

Discover the convenience
Hizentra Prefilled syringes

Elevating Patients’ Experience

Learn Why All Hizentra Patients Will Be Transitioned From Vials To Prefilled Syringes Learn more

Request more information about Hizentra

Get info and materials

Have additional questions?

Connect with CSL Behring Medical Affairs to find additional information and ask questions.

Visit Medical Affairs
References: 1. Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. Eur J Neurol. 2021;1-28. https://doi.org/10.1111/ene.14959. 2. Data on File. Available from CSL Behring as DOF HIZ-014.
acuity
You are now leaving the current website.

Do you want to continue?

No Yes